Secondary Logo

Institutional members access full text with Ovid®

Seidman Larry DO; Kroll, Robin MD; Hsieh, Jennifer MS
Obstetrics & Gynecology: May 2014
doi: 10.1097/01.AOG.0000447054.79340.0c
Tuesday, April 29, 2014: PDF Only

INTRODUCTION: This study was designed to evaluate the effect of the combined oral contraceptive regimen LeCette (150 micrograms desogestrel and 20 micrograms ethinyl estradiol for 21 days followed by 10 micrograms of ethinyl estradiol for 7 days) and two different 28-day combined oral contraceptives on ovulation inhibition and return to ovulatory capacity.

METHODS: In this phase 1, randomized, open-label comparative study, healthy, nonsmoking women aged 18–35 years with regular menstrual cycles were randomized to receive one of three combined oral contraceptives for three consecutive 28-day cycles. The three combined oral contraceptives evaluated were 21 days desogestrel and ethinyl estradiol followed by 7 days of ethinyl estradiol (desogestrel and ethinyl estradiol+ethinyl estradiol); 24 days of 3 mg drospirenone and 20 micrograms ethinyl estradiol followed by 4 placebo days (drospirenone and ethinyl estradiol and placebo); and 21 days of 100 micrograms levonorgestrel and 20 micrograms ethinyl estradiol followed by 7 placebo days (levonorgestrel and ethinyl estradiol+placebo). The proportion of women who returned to ovulatory capacity after combined oral contraceptive discontinuation was a secondary endpoint. Ovulatory capacity was defined as serum progesterone concentrations of at least 15.9 nmol/L on posttreatment cycle days 18, 19, or 20.

RESULTS: A total of 206 women were randomized, 146 were evaluated for safety, and 142 were evaluated for efficacy. Greater ovarian suppression and ovulation inhibition were observed with desogestrel and ethinyl estradiol+ethinyl estradiol and drospirenone and ethinyl estradiol+placebo compared with levonorgestrel and ethinyl estradiol+placebo during the study. Return to ovulatory capacity occurred in approximately 76% desogestrel and ethinyl estradiol+ethinyl estradiol, 75% drospirenone and ethinyl estradiol+placebo, and 58% levonorgestrel and ethinyl estradiol+placebo of women. Adverse events were comparable among groups and consistent with those observed with other combined oral contraceptives.

CONCLUSION: Regimens with altered or eliminated hormone-free intervals provided greater ovarian suppression with little delay in return to ovulatory capacity.

Financial Disclosure: Larry Seidman, DO—This author has a relevant financial relationship with the following commercial interest: Clinical Research Contractor: Clinical Research of Philadelphia, LLC. Robin Kroll, MD—This author has relevant financial relationships with the following commercial interests: Research Grants: Abbvie, Activis, Bayer, Endoceutics, and Teva Pharmaceuticals. Jennifer Hsieh, MS—This author has a relevant financial relationship with the following commercial interest: Employee: Teva Branded Pharmaceutical Products.

© 2014 by The American College of Obstetricians and Gynecologists.